Glial cell line-derived neurotrophic factor attenuates the excitotoxin- induced behavioral and neurochemical deficits in a rodent model of Huntington's disease

Neuroscience

Volumn 81, Issue 4, 1997, Pages 1099-1110

  Araujo, Dalia M ^a,b   Hilt, Dana C ^a  

^a AMGEN INC   (United States)

^b NONE   (United States)

Author keywords

GABA; Neurodegeneration; Neuropeptides; Quinolinic acid; Rotational behavior; Striatum

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLIA CELL; HUNTINGTON CHOREA; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; ROTATION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CHOLINE O-ACETYLTRANSFERASE; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUNTINGTON DISEASE; INJECTIONS, INTRAVENTRICULAR; NEOSTRIATUM; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; QUINOLINIC ACID; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR;

EID: 0031563770     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00079-1     Document Type: Article

References (78)

1. Albin R. L., Greenamyre J. T. Alternative excitotoxic hypotheses. Neurol. 42:1992;733-738.
2. Albin R. L., Young A. B., Penney J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-374.
3. Anderson K. D., Panayotatos N., Corcoran T. L., Lindsay R. M., Wiegand S. J. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington's disease. Proc. natn. Acad. Sci. U.S.A. 93:1996;7346-7351.
4. Araujo D. M., Lapchak P. A. and Hefti F. (1993) Neurotrophic factors: prospects for future use in the treatment of neurodegenerative diseases. In The Yearbook of Neurology and Neurosurgery (eds Bradley W. G. and Crowell R. M.), pp. 21-25. Mosby-Year Book Inc., U.S.A.
5. Araujo D. M., Lapchak P. A., Meaney M. J., Collier B., Quirion R. Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: relationship to presynaptic cholinergic markers and binding sites. J. Neurosci. 10:1990;3069-3078.
6. Araujo D. M., Lapchak P. A., Hefti F. Effects of chronic basic fibroblast growth factor administration to rats with partial fimbrial transections on presynaptic cholinergic parameters and muscarinic receptors in the hippocampus: comparison with nerve growth factor. J. Neurochem. 61:1993;899-910.
7. Beal M. F., Ferrante R. J., Swartz K. J., Kowall N. W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11:1991;1649-1659.
8. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., Martin J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
9. Bhide P. G., Day M., Sapp E., Schwarz C., Sheth A., Kim J., Young A. B., Penney J., Golden J., Aronin N., DiFiglia M. Expression of normal and mutant huntingtin in the developing brain. J. Neurosci. 16:1996;5523-5535.
10. Block F., Kunkel M. and Schwarz M. (1993) Quinolinic Acid Lesion of the Striatum Induces Impairment in Spatial Learning and Motor Performance in the Rat.
11. Boegman R. J., Smith Y., Parent A. Quinolinic acid does not spare striatal neuropeptide Y-immunoreactive neurons. Brain Res. 415:1987;178-182.
12. Borlongan C. V., Randall T. S., Cahill D. W., Sanberg P. R. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test. Brain Res. 676:1995;231-234.
13. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analyt. Biochem. 72:1976;248-253.
14. Burns L. H., Pakzaban P., Deacon T. W., Brownell A. L., Tatter S. B., Jenkins B. J., Isacson O. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington's disease. Neurosci. 64:1995;1001-1017.
15. Carlock L., Walker P. D., Shan Y., Gutridge K. Transcription of the Huntington's disease gene during the quinolinic acid excitotoxic cascade. NeuroReport. 6:1995;1121-1124.
16. Coyle J. T., Schwarcz R. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature. 263:1976;244-246.
17. Cross A. J., Waddington J. L. Behavioural and neurochemical studies on the striatonigral GABA pathway. Br. J. Pharmac. 66:1979;477-478.
18. Davies S. W., Beardsall K. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones. Neurosci. Lett. 140:1992;161-164.
19. Davies S. W., Roberts P. J. No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid. Nature. 327:1987;326-329.
20. Davies S. W., Roberts P. J. Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum. Neurosci. 26:1988;387-393.
21. Dawbarn D., De Quidt M. E., Emson P. C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 340:1985;251-260.
22. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13:1990;286-289.
23. Emerich D. F., Hammang J. P., Baetge E. E., Winn S. R. Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Expl Neurol. 130:1994;141-150.
24. Emerich D. F., Lindner M. D., Winn S. R., Chen E. Y., Frydel B. R., Kordower J. H. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16:1996;5168-5181.
25. Ferrante R. J., Kowall N. W., Cipollini P. B., Storey E., Beal M. F. Excitotoxic lesions in primates as a model for Huntington's disease: histopathological and neurochemical characterization. Expl Neurol. 119:1993;46-71.
26. Ferrante R. J., Kowall N. W., Richardson E. P. Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11:1991;3877-3887.
27. Ferrante R. J., Kowall N. W., Richardson E. P. Jr., Bird E. D., Martin J. B. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett. 71:1986;283-288.
28. Figueredo-Cardenas G., Anderson K. D., Chen Q., Veenman C. L., Reiner A. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Expl Neurol. 129:1994;37-56.
29. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24:1975;407-409.
30. Frim D. M., Short M. P., Rosenberg W. S., Simpson J., Breakefield X. O., Isacson O. Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. J. Neurosurg. 78:1993;267-273.
31. Frim D. M., Uhler T. A., Short M. P., Ezzedine Z. D., Klagsbrun M., Breakefield X. O., Isacson O. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. NeuroReport. 4:1993;367-370.
32. Gerfen C. R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. A. Rev. Neurosci. 15:1992;285-320.
33. Gusella J. F., MacDonald M. E. Huntington's disease: CAG genetics expands neurobiology. Curr. Opin. Neurobiol. 5:1995;656-662.
34. Heimer L., Zahm D. S. and Alheid G. F. (1995) Basal Ganglia. In The Rat Nervous System (ed. Paxinos G.), pp. 579-628. Academic Press Inc., San Diego.
35. Ho A., Gore A. C., Weickert C. S., Blum M. Glutamate regulation of GDNF gene expression in the striatum and primary striatal astrocytes. NeuroReport. 6:1995;1326-1330.
36. Humpel C., Hoffer B., Stromberg I., Bektesh S., Collins F., Olson L. Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation. Neurosci. 59:1994;791-795.
37. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 971-983.
38. Isacson O., Brundin P., Gage F. H., Bjorklund A. Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neurosci. 16:1985;799-817.
39. 2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse. 2:1988;546-557.
40. Knusel B., Winslow J. W., Rosenthal A., Burton L. E., Seid D. P., Nikolocs K., Hefti F. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin-3. Proc. natn. Acad. Sci. U.S.A. 88:1991;961-965.
41. Kordower J. H., Charles V., Bayer R., Bartus R. T., Putney S., Walus L. R., Friden P. M. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington's disease. Proc. natn. Acad. Sci. U.S.A. 91:1994;9077-9080.
42. Krogsgaard-Larsen K. Inhibitors of the GABA uptake systems. Molec. cell. Biochem. 31:1980;105-121.
43. Lapchak P. A. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev. Neurosci. 7:1997;165-176.
44. Lapchak P. A., Araujo D. M. Interleukin-2 regulates monoamine and opioid peptide release from the hypothalamus. NeuroReport. 4:1993;303-306.
45. Lapchak P. A., Araujo D. M. Effects of chronic intraventricular nerve growth factor treatment on vasoactive intestinal peptide and neuropeptide Y levels in the hippocampal formation and cerebral cortex following fimbrial transections. Brain Res. 654:1994;1-7.
46. Lapchak P. A., Araujo D. M., Hefti F. Neurotrophins in the CNS. Rev. Neurosci. 3:1992;1-10.
47. Lapchak P. A., Araujo D. M., Gash D. M., Hilt D., Hoffer B. J., Collins F. Glial cell line-derived neurotrophic factor (GDNF): pharmacological activities and application to the treatment of Parkinson's disease. Expl Neurol. 145:1997;309-321.
48. Lapchak P. A., Beck K. D., Araujo D. M., Irwin I., Langston J. W., Hefti F. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection. Neuroscience. 53:1993;639-650.
49. Lapchak P. A., Hefti F. BDNF and NGF treatment of lesioned rats: effect on cholinergic function and weight gain. NeuroReport. 3:1992;405-408.
50. Lapchak P. A., Jiao S., Collins F., Miller P. J. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res. 747:1997;72-102.
51. Lapchak P. A., Miller P. J., Collins F., Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience. 78:1997;61-72.
52. Levivier M., Holemans S., Togasaki D. M., Maloteaux J. M., Brotchi J., Przedborski S. Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol. Res. 16:1994;194-200.
53. Li S. H., Schilling G., Young W. S., Li X. J., Margolis R. L., Stine O. C., Wagster M. V., Abbott M. H., Franz M. L., Ranen N. G., Folstein S. E., Hedreen J. C., Ross C. A. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron. 11:1993;985-993.
54. Lin L.-F., Doherty D. H., Lile J. D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
55. Martin D., Miller G., Fischer N., Dix D. and Cullen T. (1997) Glial cell line-derived neurotrophic factor: the lateral cerebral ventricle is an effective site of administration for stimulation of the nigrostriatal system. Eur. J. Neurosci. (in press).
56. Martin D., Miller G., Rosendahl M., Russell D. A. Potent inhibitory effects of GDNF against kainic acid mediated seizures in rats. Brain Res. 683:1995;172-178.
57. Martin J. B., Beal M. F. Huntington's disease and neurotoxins. Ann. N. Y. Acad. Sci. 648:1992;169-175.
58. Martinez-Serrano A., Bjorklund A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci. 16:1996;4604-4616.
59. Mizuno K., Carnahan J., Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Devl Biol. 165:1994;243-256.
60. Norman A. B., Ford L. M., Sanberg P. R. Differential loss of neurochemical markers following quinolinic acid-induced lesions of rat striatum. Expl Neurol. 114:1991;132-135.
61. Norman A. B., Wyatt L. M., Hildebrand J. P., Kolmonpunporn M., Moody C. A., Lehman M. N., Sanberg P. R. Sensitization of rotation behavior in rats with unilateral 6-hydroxydopamine or kainic acid-induced striatal lesions. Pharmac. Biochem. Behav. 37:1990;755-759.
62. Paxinos G. and Watson C. (1992) The Rat Brain in Stereotaxic Coordinates (2nd edn). Academic Press, NY.
63. Pycock C. J. Turning behaviour in animals. Neurosci. 5:1980;461-514.
64. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney J. B., Young A. B. Differential loss of striatal projection neurons in Huntington disease. Proc. natn. Acad. Sci. U.S.A. 85:1988;5733-5737.
65. Sanberg P. R., Calderon S. F., Giordano M., Tew J. M., Norman A. B. The quinolinic acid model of Huntington's disease: locomotor abnormalities. Expl Neurol. 105:1989;45-53.
66. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A. B., Vonsattel J.-P., DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience. 64:1995;397-404.
67. Schmidt-Kastner R., Tomac A., Hoffer B., Bektesh S., Rosenzweig B., Olson L. Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarpine-induced status epilepticus in rats. Molec Brain Res. 26:1994;325-330.
68. Schwarcz R., Fuxe K., Agnati L. F., Hokfelt T., Coyle J. T. Rotational behavior in rats with unilateral striatal kainic acid lesions: a behavioral model for studies on intact dopamine receptors. Brain Res. 170:1979;485-495.
69. Schwarcz R., Whetsell W. O. Jr., Mangano R. M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 219:1983;316-318.
70. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc. natn. Acad. Sci. U.S.A. 86:1989;10156-10160.
71. Sharp A. H., Ross C. A. Neurobiology of Huntington's disease. Neurobiol. Disease. 3:1996;3-15.
72. Strong T. V., Tagle D. A., Valdes J., Elmer L. W., Boehm K., Swaroop M., Kaatz K. W., Collins F. S., Albin R. L. Widespread expression of the human and rat Huntington's disease gene in brain and non-neural tissues. Nature Genet. 5:1993;259-265.
73. Susel Z., Engber T. M., Kuo S., Chase T. N. Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease. Neurosci. Lett. 121:1991;234-238.
74. Tatter S. B., Galpern W. R., Hoogeveen A. T., Isacson O. Effects of striatal excitotoxicity on huntingtin-like immunoreactivity. NeuroReport. 6:1995;1125-1129.
75. Venero J. L., Beck K. D., Hefti F. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA. Neuroscience. 61:1994;257-268.
76. Ventimiglia R., Mather P. E., Jones B. E., Lindsay R. M. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur. J. Neurosci. 7:1995;213-222.
77. Vezzani A., Serafini R., Stasi M. A., Caccia S., Conti I., Tridico R. V., Samanin R. Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J. Pharmac. exp. Ther. 249:1989;278-283.
78. Yan Q., Matheson C., Sun J., Radeke M. J., Feinstein S. C., Miller J. A. Distribution of intracerebal ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Expl Neurol. 127:1994;23-36.